vs

Side-by-side financial comparison of OMEGA HEALTHCARE INVESTORS INC (OHI) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

OMEGA HEALTHCARE INVESTORS INC is the larger business by last-quarter revenue ($323.0M vs $207.3M, roughly 1.6× Ultragenyx Pharmaceutical Inc.). OMEGA HEALTHCARE INVESTORS INC runs the higher net margin — 49.1% vs -62.0%, a 111.1% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 16.7%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 13.0%).

Omega Healthcare Investors Inc is a specialized real estate investment trust that owns, leases and manages healthcare-related real estate assets, mainly including skilled nursing facilities, senior housing and long-term care facilities across the U.S. and UK. It partners with healthcare operators to provide stable real estate support for quality patient care delivery.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

OHI vs RARE — Head-to-Head

Bigger by revenue
OHI
OHI
1.6× larger
OHI
$323.0M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+9.2% gap
RARE
25.9%
16.7%
OHI
Higher net margin
OHI
OHI
111.1% more per $
OHI
49.1%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
13.0%
OHI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
OHI
OHI
RARE
RARE
Revenue
$323.0M
$207.3M
Net Profit
$158.6M
$-128.6M
Gross Margin
Operating Margin
-54.7%
Net Margin
49.1%
-62.0%
Revenue YoY
16.7%
25.9%
Net Profit YoY
41.5%
3.5%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OHI
OHI
RARE
RARE
Q1 26
$323.0M
Q4 25
$319.2M
$207.3M
Q3 25
$311.6M
$159.9M
Q2 25
$282.5M
$166.5M
Q1 25
$276.8M
$139.3M
Q4 24
$279.3M
$164.6M
Q3 24
$276.0M
$139.5M
Q2 24
$252.7M
$147.0M
Net Profit
OHI
OHI
RARE
RARE
Q1 26
$158.6M
Q4 25
$172.0M
$-128.6M
Q3 25
$179.7M
$-180.4M
Q2 25
$136.6M
$-115.0M
Q1 25
$109.0M
$-151.1M
Q4 24
$116.5M
$-133.2M
Q3 24
$111.8M
$-133.5M
Q2 24
$113.9M
$-131.6M
Operating Margin
OHI
OHI
RARE
RARE
Q1 26
Q4 25
53.7%
-54.7%
Q3 25
61.4%
-106.9%
Q2 25
52.1%
-64.8%
Q1 25
41.4%
-102.6%
Q4 24
42.5%
-74.3%
Q3 24
40.3%
-94.6%
Q2 24
47.1%
-79.1%
Net Margin
OHI
OHI
RARE
RARE
Q1 26
49.1%
Q4 25
53.9%
-62.0%
Q3 25
57.7%
-112.8%
Q2 25
48.4%
-69.0%
Q1 25
39.4%
-108.5%
Q4 24
41.7%
-80.9%
Q3 24
40.5%
-95.7%
Q2 24
45.1%
-89.5%
EPS (diluted)
OHI
OHI
RARE
RARE
Q1 26
Q4 25
$0.56
$-1.28
Q3 25
$0.59
$-1.81
Q2 25
$0.46
$-1.17
Q1 25
$0.33
$-1.57
Q4 24
$0.41
$-1.34
Q3 24
$0.42
$-1.40
Q2 24
$0.45
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OHI
OHI
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$26.1M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.2B
$-80.0M
Total Assets
$10.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OHI
OHI
RARE
RARE
Q1 26
$26.1M
Q4 25
$27.0M
$421.0M
Q3 25
$737.2M
$202.5M
Q2 25
$734.2M
$176.3M
Q1 25
$368.0M
$127.1M
Q4 24
$518.3M
$174.0M
Q3 24
$342.4M
$150.6M
Q2 24
$35.2M
$480.7M
Total Debt
OHI
OHI
RARE
RARE
Q1 26
Q4 25
$4.3B
Q3 25
$5.0B
Q2 25
$5.0B
Q1 25
$4.4B
Q4 24
$4.8B
Q3 24
$4.9B
Q2 24
$4.7B
Stockholders' Equity
OHI
OHI
RARE
RARE
Q1 26
$5.2B
Q4 25
$5.2B
$-80.0M
Q3 25
$5.0B
$9.2M
Q2 25
$5.0B
$151.3M
Q1 25
$4.7B
$144.2M
Q4 24
$4.5B
$255.0M
Q3 24
$4.2B
$346.8M
Q2 24
$3.7B
$432.4M
Total Assets
OHI
OHI
RARE
RARE
Q1 26
$10.2B
Q4 25
$10.0B
$1.5B
Q3 25
$10.6B
$1.2B
Q2 25
$10.5B
$1.3B
Q1 25
$9.7B
$1.3B
Q4 24
$9.9B
$1.5B
Q3 24
$9.6B
$1.5B
Q2 24
$8.8B
$1.6B
Debt / Equity
OHI
OHI
RARE
RARE
Q1 26
Q4 25
0.82×
Q3 25
0.99×
Q2 25
1.00×
Q1 25
0.94×
Q4 24
1.07×
Q3 24
1.15×
Q2 24
1.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OHI
OHI
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OHI
OHI
RARE
RARE
Q1 26
Q4 25
$878.6M
$-99.8M
Q3 25
$226.7M
$-91.4M
Q2 25
$239.3M
$-108.3M
Q1 25
$182.0M
$-166.5M
Q4 24
$749.4M
$-79.3M
Q3 24
$184.9M
$-67.0M
Q2 24
$184.1M
$-77.0M
Free Cash Flow
OHI
OHI
RARE
RARE
Q1 26
Q4 25
$797.7M
$-100.8M
Q3 25
$205.5M
$-92.7M
Q2 25
$226.5M
$-110.7M
Q1 25
$161.8M
$-167.8M
Q4 24
$711.7M
$-79.5M
Q3 24
$176.6M
$-68.6M
Q2 24
$177.0M
$-79.0M
FCF Margin
OHI
OHI
RARE
RARE
Q1 26
Q4 25
249.9%
-48.6%
Q3 25
65.9%
-58.0%
Q2 25
80.2%
-66.5%
Q1 25
58.4%
-120.5%
Q4 24
254.8%
-48.3%
Q3 24
64.0%
-49.2%
Q2 24
70.0%
-53.7%
Capex Intensity
OHI
OHI
RARE
RARE
Q1 26
Q4 25
25.3%
0.5%
Q3 25
6.8%
0.8%
Q2 25
4.5%
1.5%
Q1 25
7.3%
1.0%
Q4 24
13.5%
0.1%
Q3 24
3.0%
1.2%
Q2 24
2.8%
1.4%
Cash Conversion
OHI
OHI
RARE
RARE
Q1 26
Q4 25
5.11×
Q3 25
1.26×
Q2 25
1.75×
Q1 25
1.67×
Q4 24
6.43×
Q3 24
1.65×
Q2 24
1.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OHI
OHI

Rental income$266.9M83%
Other$45.2M14%
Resident fees and services$6.7M2%
Real estate tax and ground lease income$3.8M1%
Miscellaneous income$526.0K0%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons